HL-161A

HL-161A is an investigational topical small molecule therapy developed by KeChow Pharma for the treatment of solid tumors. It functions as an inhibitor of Mitogen-activated protein kinase kinase 1 (MEK1) and Mitogen-activated protein kinase kinase 2 (MEK2), which are key components of the MAPK/ERK signaling pathway frequently dysregulated in various cancers. By utilizing a topical formulation, HL-161A is designed for the localized treatment of accessible tumors, such as cutaneous malignancies or skin metastases. This approach aims to provide therapeutic benefit at the tumor site while minimizing the systemic side effects typically associated with oral MEK inhibitors. HL-161A is part of a series of topical candidates, including HL-161B, currently in the early stages of development within KeChow Pharma's oncology pipeline.